Catalog Number:C001389
Genetic Background: C57BL/6J
Reproduction:Heterozygote x WT
Strain Description
The E26 transforming sequence (ETS) transcription factor family plays a key role in the embryogenesis or determination of cell subtypes in the endocellular clusters during mammary gland development. The E74-like ETS transcription factor 5 (ELF5) gene encodes a member of the epithelial-specific ETS family of transcription factors. In addition to playing a role in the late stages of terminal differentiation of keratinocytes, ELF5 also regulates many epithelial-specific genes in tissues containing glandular epithelium, such as the salivary glands and prostate[1]. ELF5 is an important regulator in the transformation and differentiation of mammary cell subtypes and is also considered a tumor suppressor transcription factor in breast cancer[2-3].
The Elf5-Cre mice were constructed using gene editing technology to insert the P2A-Cre expression element into the endogenous Elf5 gene of mice. The expression pattern of Cre recombinase is similar to that of the endogenous gene. When this strain is crossed with mice containing loxP sites, sequence recombination between loxP sites mediated by Cre recombinase can occur in tissues such as the mammary gland and uterus of offspring mice. The heterozygotes are viable and fertile.
The TGA stop codon was replaced with the “P2A-Cre-WPRE-rBG pA” cassette.
a. Method
The Elf5-Cre mice were bred with Rosa26-LSL-tdTomato mice to generate double heterozygous offspring. Cre-mediated recombination will result in the expression of tdTomato protein in the Cre-positive cells of the offspring. The mammary gland, uterus, ovary, testis, epididymis, prostate, adrenal gland, and skin tissues of 6-week-old offspring mice were collected and immunofluorescence was used to observe the expression of tdTomato protein to determine the activity of Cre recombinase.
b. Genotype
Cre+: Elf5-Cre[KI/+]; Rosa26-LSL-tdTomato[CKI/+]
Cre-: Rosa26-LSL-tdTomato[CKI/CKI]
c. Result
1. Expression of Cre recombinase in the uterus
Figure 1. Immunofluorescence staining of the uterus in female mice. In Cre+ female mice, there was a large amount of red fluorescence from tdTomato protein in uterine cells, indicating that a large amount of Cre recombinase-mediated recombination occurred in this location. In contrast, no expression of tdTomato red fluorescence was detected in the control group (Cre-) mice, indicating the absence of Cre recombinase.
2. Expression of Cre recombinase in the female mammary gland and ovary
Figure 2. Immunofluorescence staining of the mammary glands and ovaries in female mice. In Cre+ female mice, there was a large amount of red fluorescence from tdTomato protein in the mammary gland, which was almost completely co-localized with the DAPI signal, indicating that a large amount of Cre recombinase-mediated recombination occurred in this location. In contrast, no expression of tdTomato red fluorescence was detected in the control group (Cre-) mice, indicating the absence of Cre recombinase. However, there was no red fluorescence signal from tdTomato protein in the ovary, indicating that there was no Cre recombinase-mediated recombination in this location.
3. Expression of Cre recombinase in the male reproductive system and prostate gland
Figure 3. Immunofluorescence staining of the testis, epididymis, and prostate gland in male mice. In Cre+ male mice, there was a large amount of red fluorescence in the suspected spermatogenesis region of the testis, epididymis, and prostate gland, indicating that Cre recombinase-mediated recombination occurred in these areas. In contrast, no expression of tdTomato red fluorescence was detected in the control group (Cre-) mice, indicating the absence of Cre recombinase.
4. Expression of Cre recombinase in the skin and ureters
Figure 4. Immunofluorescence staining of the skin and ureters. In Cre+ mice, there was partial red fluorescence in some cells of the skin hair follicles, some sebaceous gland cells, and the ureter, indicating that Cre recombination occurred in these areas. In contrast, no expression of tdTomato red fluorescence was detected in the control group (Cre-) mice, indicating the absence of Cre recombinase.
5. Expression of Cre recombinase in the adrenal gland
Figure 5. Immunofluorescence staining of the adrenal gland. In Cre+ mice, no red fluorescence was detected in the adrenal gland, indicating that there was no Cre recombinase-mediated recombination occurring in this area.
6. Expression of Cre recombinase in the embryonic stage placenta
Figure 6. Immunofluorescence staining of placental tissue at different embryonic stages. In Cre+ mice, a significant red fluorescent signal was detected in the placenta of embryos at E10, E15, and E18, indicating a large amount of Cre recombinase expression in this area. In contrast, no red fluorescence from tdTomato was detected in the control group (Cre-) mice, indicating the absence of Cre recombinase.
d. Summary
In the Elf5-Cre mice, the expression of Cre recombinase is mainly localized in the placenta, columnar epithelial cells of the uterus, mammary ductal epithelial cells, and some hair follicles and sebaceous gland cells of the skin. At the same time, recombination mediated by Cre recombinase can be partially detected in the ureter and testis, epididymis, and prostate gland of male mice. However, almost no recombination signal was found in the ovary and adrenal glands. The expression of Cre recombinase in this model is similar to that of the endogenous Elf5 gene in mice and has good specificity.
The Cre recombinase gene is located on chromosome 2 in Elf5-Cre mice. Please avoid using mice that have been targeted on the same chromosome for breeding.
References
[1] Lee HJ, Ormandy CJ. Elf5, hormones and cell fate. Trends Endocrinol Metab. 2012 Jun;23(6):292-8.
[2] Qu X, Li Q, Tu S, Yang X, Wen W. ELF5 inhibits the proliferation and invasion of breast cancer cells by regulating CD24. Mol Biol Rep. 2021 Jun;48(6):5023-5032.
[3] Piggin CL, Roden DL, Gallego-Ortega D, Lee HJ, Oakes SR, Ormandy CJ. ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Res. 2016 Jan 7;18(1):4.